某市医疗机构丙泊酚临床使用与管理现状分析  

Analysis of propofol’s clinical use and management within medical institutions in a specific city

作　　者：侯立丽 朱亚捷 周益众 彭楠[2] 卢泽昌 邵蓉[3] HOU Li-li;ZHU Ya-jie;ZHOU Yi-zhong;PENG Nan;LU Ze-chang;SHAO Rong(Inspection Agency,Shanghai Municipal Health Commission,SHANGHAI 200031,China;School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing JIANGSU 211198,China;The Research Center of National Drug Policy&Ecosystem,China Pharmaceutical University,Nanjing JIANGSU 211198,China)

机构地区：[1]上海市卫生健康委员会监督所,上海200031 [2]中国药科大学国际医药商学院,江苏南京211198 [3]中国药科大学国家药物政策与医药产业经济研究中心,江苏南京211198

出　　处：《中国新药与临床杂志》2025年第1期13-17,共5页Chinese Journal of New Drugs and Clinical Remedies

基　　金：上海市卫生健康委员会卫生行业临床研究青年科研课题项目(20214Y0484)。

摘　　要：目的分析某市医疗机构丙泊酚临床使用与管理现状,为规范丙泊酚的临床使用管理提供合理建议。方法通过文献回顾和专家咨询,开展问卷调查,收集166家医疗机构的丙泊酚使用和管理现状,并对医疗机构建立丙泊酚管理制度与其丙泊酚管理现状间的相关性进行Fisher精确检验。结果丙泊酚临床使用和管理过程中最主要的风险是缺乏针对丙泊酚的管理制度,医疗机构建立丙泊酚管理制度与其高警示标识管理、储存设备加锁、建立使用记录单、余液处理、丙泊酚使用管理培训、定期抽查等管理现状方面存在显著差异(P<0.01)。结论缺乏针对性的管理制度是医疗机构在临床使用和管理丙泊酚过程中面临的最大挑战。应制定并实施统一的丙泊酚管理制度,进一步对包括用药记录、药品回收、处方/调剂权限、追溯系统在内的高风险环节实施强化管理。AIM To analyze the current status of clinical use and management of propofol within medical institutions in a specific city,and to provide suggestions for standardizing the management of propofol.METHODS Through literature review and expert consultation,a questionnaire survey was conducted to collect the current status of propofol use and management in 166 medical institutions,and the Fisher’s exact test to analyze the correlation between medical institutions with propofol specification and their propofol management status.RESULTS The most significant risk in the clinical use and management of propofol was the absence of specification for propofol.There are significant differences between the establishment of propofol management system in medical institutions and the management high-alert labels,locked storage facilities,usage record,residual liquid disposal,usage training,and regular check(P<0.01).CONCLUSION The absence of specification is the biggest challenge for medical institutions in the clinical use and management of propofol.It is imperative to establish and implement the unified specification of propofol.Furthermore,it is essential to strengthen the management of key high-risk areas,including usage records,drug recycling,prescription and dispensing authority,and the enhancement of traceability systems.

关 键 词：丙泊酚 临床使用 医疗机构 医疗监管 

分 类 号：R971[医药卫生—药品]